Activ Surgical01.28.22
Activ Surgical has welcomed Manish Chand, M.D., to its advisory board.
Mand is a consultant colorectal surgeon at University College London, a professor of Surgery for Apollo Hospitals Group, and chief medical officer at The AIS Channel.
“Dr. Chand, a world-renowned surgeon and one of the leading voices in the field of colorectal surgery, is an impactful addition to Activ Surgical’s Advisory Board,” said Todd Usen, CEO, Activ Surgical. “His work on minimally invasive approaches, including TaTME, coupled with the training he has received for robotic surgery, has been groundbreaking. His background and expertise will be relied on heavily by our leadership team as we identify new use cases and applications for our ActivInsights software suite during our commercial rollout in 2022.”
Chand has been at the forefront of minimally invasive surgery for which he is recognized globally as a key opinion leader and has taught surgeons laparoscopy, transanal total mesorectal excision (TaTME) and robotic surgery in several regions worldwide. He is a respected clinical academic with research interests in fluorescence imaging, artificial intelligence (AI) and computer vision, and has been recently listed within the top 2 percent of scientists in his field based on standardized citation metrics.
“I am delighted to join Activ Surgical’s Advisory Board and look forward to working with my fellow peers and colleagues alongside the company’s leadership team to improve surgical outcomes and reduce unintended medical errors in the OR,” said Chand. “The vision that Todd and his team have established for Activ Surgical is bold, innovative and potentially market changing. I am confident that the technology the company is developing will help democratize surgical care around the world.”
The Activ Surgical Advisory Board is comprised of the foremost experts spanning various areas of surgical specialty, and is instrumental in advising the company on product strategy and development.
Activ Surgical completed the world’s first autonomous robotic surgery of soft tissue in 2018. The company's patent-protected surgical software platform–ActiveEdge–is being designed to reduce unintended and preventable surgical errors by enhancing a surgeon’s intraoperative decision making via the aggregation of surgical data from around the world. Activ Surgical is privately held, and backed by Cota Capital, BAM Funds, Magnetar Capital, MINT Venture Partners, Castor Ventures, Dream One Vision, NVIDIA, DNS Capital, Tao Capital Partners, LRVHealth, Rising Tide VC, GreatPoint Ventures (GPV) and ARTIS Ventures.
Mand is a consultant colorectal surgeon at University College London, a professor of Surgery for Apollo Hospitals Group, and chief medical officer at The AIS Channel.
“Dr. Chand, a world-renowned surgeon and one of the leading voices in the field of colorectal surgery, is an impactful addition to Activ Surgical’s Advisory Board,” said Todd Usen, CEO, Activ Surgical. “His work on minimally invasive approaches, including TaTME, coupled with the training he has received for robotic surgery, has been groundbreaking. His background and expertise will be relied on heavily by our leadership team as we identify new use cases and applications for our ActivInsights software suite during our commercial rollout in 2022.”
Chand has been at the forefront of minimally invasive surgery for which he is recognized globally as a key opinion leader and has taught surgeons laparoscopy, transanal total mesorectal excision (TaTME) and robotic surgery in several regions worldwide. He is a respected clinical academic with research interests in fluorescence imaging, artificial intelligence (AI) and computer vision, and has been recently listed within the top 2 percent of scientists in his field based on standardized citation metrics.
“I am delighted to join Activ Surgical’s Advisory Board and look forward to working with my fellow peers and colleagues alongside the company’s leadership team to improve surgical outcomes and reduce unintended medical errors in the OR,” said Chand. “The vision that Todd and his team have established for Activ Surgical is bold, innovative and potentially market changing. I am confident that the technology the company is developing will help democratize surgical care around the world.”
The Activ Surgical Advisory Board is comprised of the foremost experts spanning various areas of surgical specialty, and is instrumental in advising the company on product strategy and development.
Activ Surgical completed the world’s first autonomous robotic surgery of soft tissue in 2018. The company's patent-protected surgical software platform–ActiveEdge–is being designed to reduce unintended and preventable surgical errors by enhancing a surgeon’s intraoperative decision making via the aggregation of surgical data from around the world. Activ Surgical is privately held, and backed by Cota Capital, BAM Funds, Magnetar Capital, MINT Venture Partners, Castor Ventures, Dream One Vision, NVIDIA, DNS Capital, Tao Capital Partners, LRVHealth, Rising Tide VC, GreatPoint Ventures (GPV) and ARTIS Ventures.
